 Robert Hoyer
Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyloidosis | 1 | 2007 | 36 | 0.280 |
Why?
| | Pleural Effusion | 1 | 2007 | 47 | 0.280 |
Why?
| | Alleles | 6 | 2001 | 789 | 0.260 |
Why?
| | HLA-B Antigens | 4 | 2001 | 56 | 0.260 |
Why?
| | Jejunostomy | 1 | 2005 | 12 | 0.260 |
Why?
| | Intubation, Gastrointestinal | 1 | 2005 | 56 | 0.250 |
Why?
| | Device Removal | 1 | 2005 | 126 | 0.230 |
Why?
| | Enteral Nutrition | 1 | 2005 | 160 | 0.230 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2005 | 203 | 0.220 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 1262 | 0.180 |
Why?
| | Radiosurgery | 1 | 2022 | 299 | 0.170 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2019 | 33 | 0.170 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2019 | 37 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 261 | 0.160 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 77 | 0.150 |
Why?
| | Myeloid Cells | 1 | 2019 | 126 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 427 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1355 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2019 | 979 | 0.100 |
Why?
| | Pyrimidines | 2 | 2019 | 376 | 0.090 |
Why?
| | Sequence Analysis, DNA | 3 | 2001 | 723 | 0.080 |
Why?
| | Metolazone | 1 | 2007 | 1 | 0.070 |
Why?
| | Captopril | 1 | 2007 | 10 | 0.070 |
Why?
| | Melphalan | 1 | 2007 | 29 | 0.070 |
Why?
| | Furosemide | 1 | 2007 | 32 | 0.070 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 19 | 0.070 |
Why?
| | Thoracostomy | 1 | 2007 | 17 | 0.070 |
Why?
| | Hypoalbuminemia | 1 | 2007 | 27 | 0.070 |
Why?
| | Nephrotic Syndrome | 1 | 2007 | 24 | 0.070 |
Why?
| | Chest Tubes | 1 | 2007 | 30 | 0.070 |
Why?
| | Spironolactone | 1 | 2007 | 28 | 0.070 |
Why?
| | Thalidomide | 1 | 2007 | 28 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2019 | 2177 | 0.070 |
Why?
| | Prednisolone | 1 | 2007 | 75 | 0.070 |
Why?
| | Diuretics | 1 | 2007 | 66 | 0.070 |
Why?
| | Bevacizumab | 1 | 2007 | 115 | 0.070 |
Why?
| | Drug Resistance | 1 | 2007 | 158 | 0.070 |
Why?
| | Transplantation, Autologous | 1 | 2007 | 176 | 0.070 |
Why?
| | Serum Albumin | 1 | 2007 | 137 | 0.070 |
Why?
| | Edema | 1 | 2007 | 119 | 0.070 |
Why?
| | Anemia, Aplastic | 1 | 2006 | 30 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2007 | 284 | 0.070 |
Why?
| | Multiple Myeloma | 1 | 2007 | 93 | 0.060 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 95 | 0.060 |
Why?
| | Dexamethasone | 1 | 2007 | 317 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 498 | 0.060 |
Why?
| | Base Sequence | 5 | 2001 | 2114 | 0.060 |
Why?
| | Piperazines | 1 | 2006 | 309 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2007 | 1121 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2001 | 2785 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 663 | 0.050 |
Why?
| | Middle Aged | 5 | 2019 | 26737 | 0.050 |
Why?
| | Avipoxvirus | 1 | 2000 | 1 | 0.050 |
Why?
| | Vaccinia virus | 1 | 2000 | 27 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2000 | 37 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 304 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 2000 | 124 | 0.040 |
Why?
| | Gene Frequency | 1 | 2001 | 477 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 2000 | 137 | 0.040 |
Why?
| | Etoposide | 1 | 2019 | 148 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 183 | 0.040 |
Why?
| | Carboplatin | 1 | 2019 | 135 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 286 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2000 | 219 | 0.040 |
Why?
| | Paclitaxel | 1 | 2019 | 190 | 0.040 |
Why?
| | Pyrroles | 1 | 2019 | 181 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 1998 | 49 | 0.040 |
Why?
| | Cisplatin | 1 | 2019 | 262 | 0.040 |
Why?
| | Humans | 11 | 2022 | 114686 | 0.040 |
Why?
| | Norway | 1 | 1997 | 36 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 1998 | 1982 | 0.030 |
Why?
| | Aged | 3 | 2019 | 19074 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4411 | 0.030 |
Why?
| | Male | 4 | 2019 | 55596 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1644 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1660 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 993 | 0.030 |
Why?
| | Adult | 3 | 2019 | 30550 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6347 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3329 | 0.020 |
Why?
| | Female | 4 | 2019 | 59507 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 2 | 2000 | 152 | 0.020 |
Why?
| | Neoplasms | 1 | 2000 | 2097 | 0.020 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 63 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2006 | 198 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2006 | 143 | 0.020 |
Why?
| | Benzamides | 1 | 2006 | 169 | 0.020 |
Why?
| | Prednisone | 1 | 2006 | 229 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 718 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 1842 | 0.010 |
Why?
| | HLA-B14 Antigen | 1 | 2001 | 1 | 0.010 |
Why?
| | HLA-B44 Antigen | 1 | 2001 | 2 | 0.010 |
Why?
| | Cote d'Ivoire | 1 | 2001 | 8 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 2000 | 36 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 140 | 0.010 |
Why?
| | Gene Conversion | 1 | 2000 | 6 | 0.010 |
Why?
| | HLA Antigens | 1 | 2001 | 225 | 0.010 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2000 | 170 | 0.010 |
Why?
| | HLA-DRB1 Chains | 1 | 2000 | 98 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2000 | 413 | 0.010 |
Why?
| | Immunization Schedule | 1 | 2000 | 184 | 0.010 |
Why?
| | DNA Primers | 1 | 2000 | 510 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 797 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 2000 | 770 | 0.010 |
Why?
| | HLA-B51 Antigen | 1 | 1996 | 2 | 0.010 |
Why?
| | HLA-B35 Antigen | 1 | 1996 | 3 | 0.010 |
Why?
| | HLA-B8 Antigen | 1 | 1996 | 14 | 0.010 |
Why?
| | Antigenic Variation | 1 | 1996 | 9 | 0.010 |
Why?
| | Time Factors | 1 | 2006 | 6115 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2000 | 1737 | 0.010 |
Why?
| | Cytokines | 1 | 2000 | 1841 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2006 | 9088 | 0.010 |
Why?
|
|
Hoyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|